CL2021001046A1 - Composiciones farmacéuticas mucoadhesivas de corticoesteroides - Google Patents
Composiciones farmacéuticas mucoadhesivas de corticoesteroidesInfo
- Publication number
- CL2021001046A1 CL2021001046A1 CL2021001046A CL2021001046A CL2021001046A1 CL 2021001046 A1 CL2021001046 A1 CL 2021001046A1 CL 2021001046 A CL2021001046 A CL 2021001046A CL 2021001046 A CL2021001046 A CL 2021001046A CL 2021001046 A1 CL2021001046 A1 CL 2021001046A1
- Authority
- CL
- Chile
- Prior art keywords
- mucoadhesive
- pharmaceutical compositions
- corticosteroid
- compositions
- corticosteroid pharmaceutical
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 4
- 230000003232 mucoadhesive effect Effects 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749878P | 2018-10-24 | 2018-10-24 | |
| EP19150077 | 2019-01-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001046A1 true CL2021001046A1 (es) | 2022-01-07 |
Family
ID=68296606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001046A CL2021001046A1 (es) | 2018-10-24 | 2021-04-23 | Composiciones farmacéuticas mucoadhesivas de corticoesteroides |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12539306B2 (https=) |
| EP (3) | EP4233872B1 (https=) |
| JP (1) | JP7479362B2 (https=) |
| KR (1) | KR102862769B1 (https=) |
| CN (1) | CN113271979A (https=) |
| AU (1) | AU2019365253B2 (https=) |
| BR (1) | BR112021007140A2 (https=) |
| CA (1) | CA3116649A1 (https=) |
| CL (1) | CL2021001046A1 (https=) |
| CO (1) | CO2021005913A2 (https=) |
| DK (1) | DK3870226T3 (https=) |
| ES (2) | ES2956849T3 (https=) |
| FI (2) | FI3870226T3 (https=) |
| MX (1) | MX2021004537A (https=) |
| PL (2) | PL3870226T3 (https=) |
| WO (1) | WO2020084530A1 (https=) |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| US5554380A (en) | 1994-08-04 | 1996-09-10 | Kv Pharmaceutical Company | Bioadhesive pharmaceutical delivery system |
| US6319513B1 (en) | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
| US20010016577A1 (en) | 1998-08-24 | 2001-08-23 | Douglas Joseph Dobrozsi | Oral mucoadhesive compositions containing gastrointestinal actives |
| WO2001028515A1 (en) * | 1999-10-22 | 2001-04-26 | Líf-Hlaup ehf. Bio-Gels Pharmaceuticals Inc. | Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| PT1997478E (pt) | 2001-02-15 | 2013-12-10 | Access Pharma Inc | Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas |
| US7544348B2 (en) | 2001-02-15 | 2009-06-09 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| EP1531837A4 (en) * | 2001-06-07 | 2006-11-15 | Chiou Consulting Inc | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF APHTEOUS ULCERS AND LESIONS DUE TO HERPES |
| US20030059446A1 (en) * | 2001-09-18 | 2003-03-27 | Kulkarni Arun B. | Physically stable sprayable gel composition |
| US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
| JP2007522077A (ja) * | 2003-08-21 | 2007-08-09 | アクセス ファーマシューティカルズ， インコーポレイテッド | 粘膜の疾患および障害の予防および処置のための液体製剤 |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| US20090149433A1 (en) | 2007-11-13 | 2009-06-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| CN101969956B (zh) * | 2007-11-13 | 2014-03-05 | 梅里蒂奇制药公司 | 皮质类固醇组合物 |
| US8865692B2 (en) | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| CA2723215A1 (en) | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| US8030297B2 (en) * | 2008-05-14 | 2011-10-04 | Otonomy, Inc. | Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders |
| ES2358158T3 (es) | 2008-07-21 | 2011-05-06 | Dr. Falk Pharma Gmbh | Formulación farmacéutica para el tratamiento del tracto digestivo superior. |
| HUE051538T2 (hu) | 2008-08-20 | 2021-03-01 | Univ California | Kortikoszteroidok a gyomor-bél traktus gyulladásos betegségeinek kezelésére |
| AU2009322556A1 (en) | 2008-12-01 | 2011-07-21 | Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
| MX2011013061A (es) * | 2009-06-05 | 2012-02-28 | Aciex Therapeutics Inc | Formulaciones oftalmicas de fluticasona y metodos de uso. |
| WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| JP5833007B2 (ja) | 2009-08-31 | 2015-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ステロイドを含む局所製剤 |
| MX364947B (es) | 2009-10-01 | 2019-05-15 | Adare Pharmaceuticals Inc | Composiciones de corticosteroides administradas oralmente. |
| EP3970726A1 (en) * | 2010-06-24 | 2022-03-23 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
| CN103974706A (zh) | 2011-10-06 | 2014-08-06 | N·V·努特里奇亚 | 嗜酸细胞性食管炎的治疗 |
| WO2014074995A1 (en) * | 2012-11-09 | 2014-05-15 | Scidose, Llc | Enema composition for treatment of ulcerative colitis having long term stability |
| EP2938327B1 (en) | 2012-12-26 | 2017-12-06 | Otic Pharma Ltd. | Foamable otic pharmaceutical compositions |
| WO2014155397A1 (en) | 2013-03-29 | 2014-10-02 | Italchimici S.P.A. | Oral suspension for treating eosinophilic esophagitis |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| PT2886108T (pt) | 2013-12-23 | 2019-04-01 | Dr Falk Pharma Gmbh | Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago |
| US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
| CA2946373C (en) * | 2014-05-01 | 2018-07-31 | Integral Biosystems Llc | Membrane-adherent self-assembled systems for treatment of ocular disorders |
| US11623008B2 (en) | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
| DE102014119576A1 (de) * | 2014-12-23 | 2016-06-23 | Ernst-Moritz-Arndt-Universität Greifswald | Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten |
| US20180140619A1 (en) * | 2015-05-04 | 2018-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivering therapeutic agents into the colon |
| BR102018008324A2 (pt) | 2018-04-25 | 2019-11-05 | Laboratorios Ferring Ltda | composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico |
-
2019
- 2019-10-23 FI FIEP19790866.8T patent/FI3870226T3/fi active
- 2019-10-23 PL PL19790866.8T patent/PL3870226T3/pl unknown
- 2019-10-23 EP EP23181722.2A patent/EP4233872B1/en active Active
- 2019-10-23 WO PCT/IB2019/059079 patent/WO2020084530A1/en not_active Ceased
- 2019-10-23 EP EP19790866.8A patent/EP3870226B1/en active Active
- 2019-10-23 MX MX2021004537A patent/MX2021004537A/es unknown
- 2019-10-23 ES ES19790866T patent/ES2956849T3/es active Active
- 2019-10-23 AU AU2019365253A patent/AU2019365253B2/en active Active
- 2019-10-23 DK DK19790866.8T patent/DK3870226T3/da active
- 2019-10-23 BR BR112021007140-7A patent/BR112021007140A2/pt unknown
- 2019-10-23 ES ES23181722T patent/ES3043383T3/es active Active
- 2019-10-23 KR KR1020217011830A patent/KR102862769B1/ko active Active
- 2019-10-23 US US17/288,385 patent/US12539306B2/en active Active
- 2019-10-23 CN CN201980084843.5A patent/CN113271979A/zh active Pending
- 2019-10-23 FI FIEP23181722.2T patent/FI4233872T3/fi active
- 2019-10-23 JP JP2021521814A patent/JP7479362B2/ja active Active
- 2019-10-23 EP EP25186229.8A patent/EP4603097A3/en active Pending
- 2019-10-23 CA CA3116649A patent/CA3116649A1/en active Pending
- 2019-10-23 PL PL23181722.2T patent/PL4233872T3/pl unknown
-
2021
- 2021-04-23 CL CL2021001046A patent/CL2021001046A1/es unknown
- 2021-05-05 CO CONC2021/0005913A patent/CO2021005913A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022505535A (ja) | 2022-01-14 |
| MX2021004537A (es) | 2021-06-15 |
| AU2019365253A1 (en) | 2021-05-27 |
| FI3870226T3 (fi) | 2023-09-15 |
| ES2956849T3 (es) | 2023-12-29 |
| FI4233872T3 (fi) | 2025-10-02 |
| DK3870226T3 (da) | 2023-09-18 |
| CO2021005913A2 (es) | 2021-05-20 |
| ES3043383T3 (en) | 2025-11-25 |
| PL3870226T3 (pl) | 2023-12-27 |
| EP3870226B1 (en) | 2023-06-28 |
| US12539306B2 (en) | 2026-02-03 |
| CN113271979A (zh) | 2021-08-17 |
| JP7479362B2 (ja) | 2024-05-08 |
| CA3116649A1 (en) | 2020-04-30 |
| WO2020084530A1 (en) | 2020-04-30 |
| EP4233872A3 (en) | 2023-10-11 |
| EP4233872A2 (en) | 2023-08-30 |
| EP3870226A1 (en) | 2021-09-01 |
| EP4233872B1 (en) | 2025-07-02 |
| US20210379081A1 (en) | 2021-12-09 |
| EP4603097A3 (en) | 2025-10-22 |
| AU2019365253B2 (en) | 2025-02-20 |
| KR20210088547A (ko) | 2021-07-14 |
| EP4603097A2 (en) | 2025-08-20 |
| KR102862769B1 (ko) | 2025-09-19 |
| BR112021007140A2 (pt) | 2021-07-20 |
| PL4233872T3 (pl) | 2025-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| CL2017002693A1 (es) | Métodos para tratar infecciones por el virus filoviridae. divisional de solicitud n° 1040-2017. | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CY1124554T1 (el) | Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| CR20190394A (es) | Compuestos de inhibidores de autotaxina | |
| MX2019009185A (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| CO6680695A2 (es) | Formulaciones farmacéuticas que contienen rifaximina procesos para su obtención y método para tratar enfermedad intestinal | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| CL2022003703A1 (es) | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| MX2019012051A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| MX2024012972A (es) | Vedolizumab para el tratamiento de pacientes pediatricos | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MX378931B (es) | Metodos para tratar y prevenir enfermedades de inestabilidad vascular. |